Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
about
Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?Optimum dose of olsalazine for maintaining remission in ulcerative colitis.Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study.Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Mesalamine with MMX technology for the treatment of ulcerative colitis.Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Nanotechnology in the treatment of inflammatory bowel diseases.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.The long journey of salicylates in ulcerative colitis: The past and the future.Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis.Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine.Recent advances in the management of distal ulcerative colitis.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.An alternative view of 5-ASA formulations.Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.Colon-specific delivery of mesalazine chitosan microspheres.
P2860
Q33406895-D2EAEBD3-99E7-4A8A-80D3-AE7E67BF75DDQ33701611-DA806666-E7F4-41EA-9C6E-90A717F33A5DQ33868970-93CF3A05-E0BB-4F1D-AA2D-E012DEDA433EQ34382072-5D6F5974-ECF6-4C49-B7A2-315E9D5511ABQ35361187-654808D7-2769-432D-920E-35D813127049Q35928671-7311258C-712F-42B7-8C4E-0B7BED2C798BQ36055120-9962C391-4115-4173-8B19-CAD880B34B70Q36144377-BCC13A12-D647-47DD-AF41-38D3D705EAC4Q37345925-0034B574-FA3B-45E0-B2A5-571F387F2741Q37850826-0D3F82AA-C6F9-4903-B6E3-B9D9B79D0D18Q37892884-5F3E5731-08A6-44D9-8DF7-74BE7E75B901Q38200842-51188B33-4115-4417-9055-D52C1A78A047Q38288749-EF53B70E-E299-48AB-87F7-0B60901A2FD4Q38571119-7AF850D5-7AF6-4CF1-8329-D808C9018E92Q40651677-B7C40C0C-2346-48AE-9C36-0E5E0B31A0FAQ41903886-63C187EF-0A61-4233-A777-5AC629DC7927Q42169283-B4051D91-093B-4980-9D8E-C77E71746D31Q42491622-E7BE61BE-F679-4560-9428-560F0F5E3154Q42730491-21BDB104-7D6B-4A36-B82A-E6C813E407F5Q42877648-1E135D07-82AD-4A53-9B12-824EE172CAF7Q43188703-46DC7CA5-9666-4D7D-BA91-0CEC90A6CDB4Q43225494-32D84737-85FB-4B09-882E-10942B62E32BQ43514773-D77813AE-80A8-4FBA-B2BE-FBEB8CCE9E34Q43714774-3A8F1E9C-2B15-49A0-86B7-DE01E83A5248Q43769282-CEB23725-7CFC-4EAA-B7F2-990E60639B85Q46559874-5ECF9925-669B-46C7-92C3-83F1DE56A207Q51172914-F6FDC8C3-2A18-4B5D-8003-0928A6263899
P2860
Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@ast
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@en
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@nl
type
label
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@ast
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@en
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@nl
prefLabel
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@ast
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@en
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@nl
P2093
P2860
P356
P1433
P1476
Concentrations of 5-ASA and Ac ...... after oral 5-ASA preparations.
@en
P2093
P2860
P304
P356
10.1136/GUT.33.10.1338
P407
P577
1992-10-01T00:00:00Z